The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →No. CRISPR has not been shown to cure HIV in people. The leading human example, EBT-101, is an experimental gene therapy tested in only six adults. A 2025 review reports that all three participants who temporarily stopped antiretroviral therapy (ART) under the study protocol experienced viral rebound. That is not ART-free control, and it is not evidence of a cure.
People living with HIV should continue ART exactly as prescribed. An analytical treatment interruption is a monitored research procedure, not a treatment experiment to attempt at home.
As an Amazon Associate I earn from qualifying purchases.
What would “cure” mean in HIV?
HIV treatment already suppresses the virus to levels that routine tests may not detect, but suppression depends on continuing ART. A cure claim would require evidence that HIV remains controlled without ongoing medication. Researchers may also distinguish between eliminating all replication-competent virus and achieving durable post-treatment control without eradicating every infected cell. Either result would require carefully monitored clinical evidence, not a single undetectable viral-load test.
Recommended Free Tools
That distinction matters because HIV can persist as integrated viral DNA inside long-lived cells. ART blocks new rounds of infection and replication, but it does not reliably remove every silent viral copy. If medication is stopped, those reservoirs can sometimes produce virus again.
#1 Best Overall
How an HIV-targeted CRISPR therapy is supposed to work
EBT-101 targets viral DNA
EBT-101 is designed to use CRISPR/Cas9 molecular scissors to recognize specific HIV DNA sequences. The intended result is to cut the integrated viral genome so that infected cells can no longer produce functional virus. This is different from conventional ART, which suppresses replication without directly excising integrated HIV DNA.
The EBT-101 first-in-human Phase 1/2a study delivered the gene-editing system through an adeno-associated virus serotype 9 (AAV9) vector by intravenous infusion. Participants were adults with HIV-1 whose virus was suppressed on stable ART. The protocol included an assessment of whether an analytical treatment interruption could be conducted safely enough to observe viral control after dosing.
Because the therapy is delivered through the bloodstream, it must reach the relevant tissues and infected-cell populations, enter those cells, release the CRISPR components, and cut the correct viral sequences. HIV is genetically diverse, and latent infected cells are distributed through the body. Those biological and delivery barriers are central reasons a promising laboratory mechanism does not automatically become a human cure.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What the study record says
The ClinicalTrials.gov record for NCT05144386, last updated December 2, 2024, lists six enrolled participants. It describes the study design and safety outcome measures but has no posted results in the registry record. The listing shows the study as completed on November 14, 2024; completion of a trial does not itself establish that its intervention worked.
What happened when participants interrupted ART?
A 2025 peer-reviewed review of post-intervention HIV control reports that EBT-101 was evaluated in six people with suppressed HIV and that three participants underwent analytical treatment interruption. All three experienced viral rebound. In practical terms, the single dose did not maintain ART-free viral suppression in those participants.
That result does not answer every future question. It does not establish whether a different CRISPR target, repeat dosing, another delivery vehicle, or a combination with an immune-based treatment could perform better. It does show that the human evidence currently available does not demonstrate durable control after stopping ART.
The review is available in full at “CRISPR/Cas9 for achieving postintervention HIV control” (2025). Its outcome summary is more informative about the three treatment interruptions than the registry, which had not posted participant-level results when retrieved.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Is EBT-101 an available HIV treatment?
No. EBT-101 remains an investigational intervention studied in a small early-phase trial. It is not an approved replacement for ART, and the public evidence does not establish a population-level success rate.
Early-phase studies primarily determine whether an intervention can be given safely and provide preliminary signals of biological activity. The NIH explains that “A clinical trial is a research study in which people volunteer to help find answers to specific health questions.” The NIH HIVinfo clinical-trials guide, reviewed September 16, 2025, describes why investigational medicines must pass through staged studies before they can be considered for general use.
Because the EBT-101 registry record did not post results, it also does not provide a complete public accounting of participant-level safety findings. Absence of posted results is not proof that an adverse event occurred or that the treatment was unsafe; it means the registry entry cannot be used to make a definitive safety or efficacy judgment.
CRISPR removal and CCR5 editing are different strategies
Another gene-editing approach changes a human immune-cell gene called CCR5. Many HIV strains use the CCR5 receptor to enter CD4 T cells. The goal of CCR5 editing is therefore to make some immune cells less susceptible to new infection, rather than cutting HIV DNA already integrated into cells.
That distinction is important when reading headlines. A therapy that modifies CCR5 is not the same as an in-vivo CRISPR system designed to excise HIV DNA. It may affect the supply of susceptible cells without removing the reservoir that already exists.
The NIH SB-728-T patient drug record describes this CCR5-modifying strategy as investigational. It notes partial viral-load control during an analytical treatment interruption, while results presented at CROI 2025 found that CCR5-modified T cells did not reduce the HIV reservoir more than unmodified T cells in the comparison described. Those observations do not establish an HIV cure and should not be combined with the EBT-101 results as though they were the same treatment.
| Approach | Primary target | Delivery or cell handling | Human evidence described | What it shows |
|---|---|---|---|---|
| EBT-101 | Integrated HIV DNA | CRISPR/Cas9 carried by an AAV9 vector and infused intravenously | Six participants enrolled; three underwent analytical treatment interruption and all three had viral rebound, according to a 2025 review | No demonstrated ART-free control in the reported participants |
| SB-728-T | Host CCR5 receptor in immune cells | Investigational modification of immune cells | NIH record reports partial viral-load control during an interruption; CROI 2025 comparison found no greater reservoir reduction than unmodified T cells | A different, investigational strategy; not proof of reservoir eradication |
| 2014 CCR5 study | Host CCR5 gene | Patients’ own CD4 T cells modified outside the body and reinfused | Four evaluable participants; HIV RNA became undetectable in one, and blood HIV DNA decreased in most | Historical proof of concept for another editing method, not a CRISPR cure |
Why the 2014 CCR5 result is not a CRISPR cure
The frequently cited 2014 study in the New England Journal of Medicine used zinc-finger nucleases, not CRISPR/Cas9. Researchers modified each participant’s own CD4 T cells and returned them by infusion. It was a small, uncontrolled study. HIV RNA became undetectable in one of four evaluable participants, and blood HIV DNA declined in most participants; the authors concluded that the infusions were safe within the limits of that study.
Those findings supplied evidence that targeted editing of human immune cells could be performed and might influence HIV measurements. They did not show that all HIV had been removed, that participants could remain controlled without ART, or that the technique was CRISPR. The original report is “Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV”.
How to interpret viral rebound
During an analytical treatment interruption, clinicians stop ART under a study protocol and monitor viral load, immune markers, symptoms, and safety. If HIV becomes detectable again, that is viral rebound. In the EBT-101 report, rebound in all three participants who interrupted treatment indicates that the intervention did not provide sustained control for those individuals during the observed interruption.
Best Value
Rebound is not the same measurement as the size of the latent reservoir. A therapy could alter reservoir markers without preventing renewed viremia, or it could delay rebound without eliminating HIV. That is why a credible cure claim needs several kinds of evidence rather than one laboratory result.
What evidence would be needed for a convincing cure claim?
- Durable ART-free control: Participants would need to remain virally suppressed for a meaningful observation period after a protocol-defined interruption, with frequent safety monitoring.
- Reservoir assessment: Studies would need sensitive measurements of HIV DNA and, ideally, replication-competent virus rather than relying only on a routine viral-load result.
- Reproducibility: Findings would need to appear in more than a handful of participants and be confirmed by independent investigators or larger controlled studies.
- Safety characterization: Researchers would need to report infusion reactions, immune effects, off-target editing, vector-related risks, and longer-term outcomes.
- Clear comparison with ART: The study would need to explain how participants were selected, how interruption decisions were made, and whether any benefit exceeded what is achievable with continued standard treatment.
The current EBT-101 evidence does not meet that standard. Its small enrollment, lack of posted registry results, and reported rebound after interruption leave substantial questions about effectiveness and durability.
What this means for someone taking ART
Do not stop, skip, or change ART because of CRISPR news. In the EBT-101 study, treatment interruption was an analytical procedure carried out within a clinical protocol. It was not a recommendation for routine care, and unsupervised interruption can allow HIV to rebound and may create avoidable health risks.
Free tools Windows power users keep installed
One-click scans. No signup required.
Anyone considering an investigational HIV study should discuss eligibility, known and unknown risks, contraception and medication requirements, monitoring schedules, and the interruption rules with the study team and their HIV clinician. A trial listing is an invitation to evaluate participation with professionals, not evidence that the intervention is available treatment.
What to watch as the field develops
Future updates should be judged against the primary trial record and peer-reviewed participant data. Check whether the EBT-101 registry entry adds results, whether a publication reports outcomes for all six enrolled participants, and whether later studies test repeat dosing, alternative delivery, or combination approaches. Pay particular attention to the number of people who interrupt ART, the duration of follow-up, the frequency and timing of rebound, reservoir measurements, and the complete safety report.
As of the available record and the 2025 review, CRISPR remains a promising but unproven research direction for HIV. The human data describe an important test of feasibility, not a treatment that has achieved cure.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
